Novavax, Inc. $NVAX Stock Holdings Lifted by Virtus Investment Advisers LLC

Virtus Investment Advisers LLC raised its position in shares of Novavax, Inc. (NASDAQ:NVAX) by 56.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 62,153 shares of the biopharmaceutical company’s stock after purchasing an additional 22,348 shares during the quarter. Virtus Investment Advisers LLC’s holdings in Novavax were worth $392,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of NVAX. Quadrature Capital Ltd purchased a new stake in shares of Novavax in the second quarter worth approximately $191,000. Russell Investments Group Ltd. increased its stake in Novavax by 47,125.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,557 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 24,505 shares during the period. Prudential Financial Inc. increased its stake in Novavax by 222.2% in the 2nd quarter. Prudential Financial Inc. now owns 37,066 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 25,563 shares during the period. Rhumbline Advisers boosted its stake in shares of Novavax by 7.7% during the 2nd quarter. Rhumbline Advisers now owns 231,917 shares of the biopharmaceutical company’s stock valued at $1,461,000 after buying an additional 16,504 shares during the period. Finally, TSP Capital Management Group LLC boosted its stake in shares of Novavax by 3.5% during the 2nd quarter. TSP Capital Management Group LLC now owns 1,399,065 shares of the biopharmaceutical company’s stock valued at $8,814,000 after buying an additional 46,900 shares during the period. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Price Performance

Shares of NASDAQ:NVAX opened at $7.02 on Friday. The company has a market cap of $1.14 billion, a price-to-earnings ratio of 3.08, a PEG ratio of 0.12 and a beta of 2.68. The business has a 50 day moving average price of $8.03 and a 200 day moving average price of $7.61. The company has a quick ratio of 2.34, a current ratio of 2.36 and a debt-to-equity ratio of 5.93. Novavax, Inc. has a twelve month low of $5.01 and a twelve month high of $11.55.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.08) by ($0.17). Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The business had revenue of $70.45 million during the quarter, compared to the consensus estimate of $55.63 million. During the same period in the prior year, the firm earned ($0.76) earnings per share. The business’s quarterly revenue was down 16.7% on a year-over-year basis. Novavax has set its FY 2025 guidance at EPS. Research analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on NVAX. HC Wainwright lifted their price objective on Novavax from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. JPMorgan Chase & Co. reduced their price target on Novavax from $7.00 to $6.00 and set an “underweight” rating for the company in a report on Tuesday, November 18th. TD Cowen lowered their price target on Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a research note on Tuesday, November 4th. Weiss Ratings restated a “sell (d)” rating on shares of Novavax in a report on Tuesday. Finally, Cantor Fitzgerald began coverage on shares of Novavax in a research report on Friday, October 24th. They set an “overweight” rating and a $18.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $11.25.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.